TY - JOUR T1 - Tocilizumab in COVID-19 management: addressing time of starting treatment JF - European Journal of Hospital Pharmacy JO - Eur J Hosp Pharm SP - e9 LP - e9 DO - 10.1136/ejhpharm-2021-003149 VL - 30 IS - 2 AU - Sajad Khiali AU - Taher Entezari-Maleki Y1 - 2023/03/01 UR - http://ejhp.bmj.com/content/30/2/e9.abstract N2 - Identifying effective and safe therapies for the management of patients with coronavirus disease 2019 (COVID-19) is crucial in the control of the pandemic. The critical role of immune system dysregulation in the pathophysiology of multisystem organ dysfunction following COVID-19 is well recognised. Several attempts have been made to investigate multiple anti-inflammatory drugs with beneficial effects in the management of COVID-19. Recently, the US Food and Drug Administration issued an emergency use authorisation (EUA) for the use of tocilizumab in combination with corticosteroids in hospitalised patients with COVID-19 aged ≥2 years who require non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation. However, there are uncertainties regarding the time, dose and duration of administration. Some efforts have been made to answer these questions.1 2 … ER -